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A B S T R A C TObjective: This study was designed to examine the psychometric
properties and measurement equivalence of the English and Chinese
versions of the Functional Assessment of Cancer Therapy-Cognitive
Function (Version 3) (FACT-Cog) in multiethnic Asian patients with
breast cancer. Methods: This prospective study involved patients
with breast cancer from the National Cancer Centre Singapore. The
concurrent validity of the FACT-Cog was assessed according to its
strength of correlation with the validated European Organization for
Research and Treatment of Cancer Quality of Life Core Questionnaire
30 cognitive functioning scale, and its association with fatigue,
global health status, and anxiety. The known-group validity was
assessed on the basis of receipt of chemotherapy. Factor analysis
was conducted to ascertain the one-factor structure of each cogni-
tive domain. The reliability was evaluated by using Cronbach’s alpha
and intraclass correlation coefﬁcient within the cognitive domains.
Multiple regression analyses were performed to compare the total
scores between the two language versions, adjusting for covariates.
Results: A total of 185 English-speaking and 143 Chinese-speaking
patients were recruited. Both the English and Chinese FACT-Cog
total scores correlated strongly with the European Organization forsee front matter Copyright & 2013, International S
r Inc.
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are co-ﬁrst authors of this study.Research and Treatment of Cancer Quality of Life Core Questionnaire
30 cognitive functioning scale scores (r ¼ 0.725 and 0.646), whereas
correlations with fatigue, anxiety, and global health status were
weak to moderate (|r| ¼ 0.376–0.589). Regarding the known-group
validity, more severe perceived cognitive disturbance was observed
among patients receiving chemotherapy than among those who
were not for both versions (P ¼ .010 and .008, respectively). Internal
consistencies within the cognitive domains were high (Cronbach’s α
0.707–0.929), and test-retest reliability was satisfactory for both
versions (intraclass correlation coefﬁcient 0.762 and 0.697). The meas-
urement equivalence between the English and Chinese versions was
established for all domains except the multitasking domain. Conclu-
sion: The English and Chinese versions of the FACT-Cog are valid,
reliable, and equivalent for clinical and research use.
Keywords: breast cancer, chemobrain, chemofog, chemotherapy,
cognitive function, FACT-Cog, psychooncology, quality of life,
validation.
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Outcomes Research (ISPOR). Published by Elsevier Inc.Introduction
A substantial amount of research has suggested that cognitive
impairment affects 19% to 78% of the patients with breast cancer
[1–4]. In the literature, the terms “chemobrain” and “chemofog”
have been used to refer to the subtle yet notable deterioration in
patients’ cognitive domains, which include memory, concentra-
tion, mental acuity, learning, processing speed, and executive
functioning. To emphasize, this worsening of cognitive function
may be subtle, but studies have shown that it can have a
detrimental effect on the health-related quality of life (HRQOL)
and functional independence of patients with breast cancer [5–7].
The Functional Assessment of Cancer Therapy-Cognitive
Function (FACT-Cog), currently in its third version, is aquestionnaire that evaluates patients’ self-reported perceptions
of their cognitive abilities and the effects of these cognitive
changes on their HRQOL [8,9]. The FACT-Cog distinguishes itself
from other available subjective neuropsychological tests because
the questionnaire focuses on the noticeability and functional
interference of the multiple speciﬁc domains associated with
perceived cognitive functioning. The FACT-Cog has been used in
several studies to assess the presence of subjective cognitive
deﬁcits in patients with cancer [1,10–13]. There is currently
limited data on psychometric properties of the FACT-Cog. An
older version of the FACT-Cog (version 2) was validated within
the hematopoetic stem cell transplant population [13]. The FACT-
Cog (version 3) is available in French, and it has yielded good
linguistic validation results within French patients with cancerociety for Pharmacoeconomics and Outcomes Research (ISPOR).
clare.
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however, have not been validated for use in research and clinical
settings within the Asian population with breast cancer. Speciﬁc
research on the reliability and other measurement properties of
the Chinese version of the FACT-Cog has also not been published
in the literature.
Because there is evidence in the literature to show that
ethnicity, language, and cultural preferences can inﬂuence
patients’ perception of cognitive functioning [5,15], the validation
of the English and Chinese versions of the FACT-Cog within
Asian patients with breast cancer is essential to determine
whether its results can be used with conﬁdence as a reliable
instrument in future epidemiological studies and clinical trials.
Establishing the equivalence between the English and Chinese
versions of the FACT-Cog will also allow the results from both
languages to be pooled for future research. Hence, we designed
this study to evaluate the validity of the English and Chinese
versions of the FACT-Cog in the context of a multiethnic Asian
population with breast cancer, and to determine the measure-
ment equivalence between these two versions.Methods
Study and Setting
This prospective study was conducted at the outpatient clinics of
the National Cancer Centre Singapore from November 2010 to
August 2012. The National Cancer Centre Singapore is the largest
ambulatory cancer center in Singapore and treats 70% of the
annual cancer population. This study was approved by the
Singhealth Institutional Review Board.
Patients
The patients who were recruited to participate in this study were
histologically diagnosed with breast cancer by a medical oncol-
ogist, were at least 18 years old, were ambulatory in nature
(deﬁned as having an Eastern Cooperative Oncology Group
performance status score of 0 or 1), spoke English or Chinese as
their mother tongue, and were willing to give informed consent.
Patients were excluded from the study if breast cancer was a
secondary malignancy, or patients presented with evidence of
brain metastasis, psychosis, or any underlying neuropsychiatric
illness that might impair their cognitive abilities. Patients’ med-
ical histories and medication records (extracted from a compre-
hensive in-house database) were reviewed to ensure that they
had not been prescribed neuropsychiatric or psychotropic med-
ications. Patients were classiﬁed into English-speaking and
Chinese-speaking on the basis of their indicated mother tongue
or preferred choice of language for routine reading (e.g., news-
papers and books), writing, and communication. Eligible patients
were recruited from the outpatient clinics to ensure a heteroge-
neous and representative sample of patients (in terms of treat-
ment status and time since diagnosis of cancer) for this
validation study.
Study Procedures
The patients’ demographic and medical information was
obtained from the existing electronic databases available at the
National Cancer Centre Singapore. Data on patients’ cancer
treatment, chemotherapy protocol, and the use of complemen-
tary alternative medicine such as traditional Chinese medicine
and vitamins or other nutritional products were also collected.
Three questionnaires—the FACT-Cog, the European Organization
for Research and Treatment of Cancer Quality of Life Core
Questionnaire 30 (EORTC-QLQ-C30) cognitive functioning scale,and the Beck Anxiety Inventory (BAI)—were administered to
patients by interviewers on recruitment. English and Chinese
versions were available for all questionnaires, and these were
administered to the English-speaking and Chinese-speaking groups,
respectively. All interviewers were bilingual and underwent training
to ensure consistency in questionnaire administration.
Tools
FACT-Cog
The FACT-Cog contains 37 items, with subscales created by the
developers consisting of 1) patients’ perceived cognitive impair-
ments, 2) perceived cognitive abilities, 3) noticeability or com-
ments from others, and 4) impact of cognitive changes on quality
of life [16]. A global or summary score is obtained by summing all
the item scores. Given that our focus here was to examine the
psychometric properties and measurement equivalence of the
FACT-Cog based on its cognitive domains, items in subscales 1)
and 2) were regrouped into their cognitive domains before data
analysis, according to the developer’s original classiﬁcations and
the expertise of a neuropsychologist in our research team [9,17].
This approach was adopted so as to facilitate the mapping of
patient-reported cognitive outcomes from the FACT-Cog with the
individual cognitive domains of objective neuropsychological test
performances in future studies [18,19]. Hence, this study involved
the validation of subscales 3) and 4) and the six reclassiﬁed
cognitive domains of interest: mental acuity, attention and
concentration, memory, verbal ﬂuency, functional interference,
and multitasking ability (Table 1). The items are rated for the
previous week, including the day of administration. Each item is
rated on a ﬁve-point Likert scale, ranging from 0 (“Never” or “Not
at all”) to 4 (“Several times a day” or “Very much”). The total score
for the FACT-Cog can range from 0 to 148 points, with a higher
score indicative of better perceived cognitive functioning.
The English version of the FACT-Cog was translated into
simpliﬁed Chinese by investigators proﬁcient in both languages.
The translation closely followed the guidelines stipulated by the
Translation and Cultural Adaptation-Principles of Good Practice
[20]. The questionnaire was forward- and backward translated,
reconciled by independent parties, and underwent cognitive
pretesting with a representative and culturally homogeneous
sample of 30 bilingual Singaporean patients to identify items
that were offensive and/or structurally difﬁcult to understand
within the local context [5,20]. The ﬁnal reconciled version was
approved by the Functional Assessment of Chronic Illness
Therapy.
The EORTC-QLQ-C30
The EORTC-QLQ-C30 (referred to as QLQ-C30 hereafter) is a
questionnaire developed to assess cancer patients’ HRQOL [21].
It contains 30 items that are grouped into ﬁve functional domains
(physical, role, cognitive, emotional, and social), three symptom
domains (fatigue, pain, and nausea/vomiting), a global quality-of-
life domain, and six individual items (dyspnea, insomnia, ano-
rexia, diarrhea, constipation, and ﬁnancial stability). Items are
rated for the previous week, including the present day. Each of
the items, with the exception of the global quality-of-life domain,
is rated on a four-point Likert scale, ranging from 1 (“Not at all”)
to 4 (“Very much”). The global quality-of-life domain is rated on a
seven-point Likert scale, with 1 being “very poor” and 7 being
“excellent.” The score for each domain ranges from 0 to 100
points. Higher scores in the functional and global quality-of-life
domains are indicative of better functioning or health status,
while higher scores in the symptom domains and individual
symptom items are indicative of worse symptoms. Both the
English and Chinese versions of the QLQ-C30 have been validated
within the cancer population in Singapore [22].
Table 1 – Items listed in English, internal consistencies of each domain/scale (as depicted by Cronbach's α), and item-to-domain/scale correlations.
Combined FACT-Cog English
and Chinese versions
(N ¼ 328)
FACT-Cog English version
(n ¼ 185)
FACT-Cog Chinese version
(n ¼ 143)*
Domain/
Scale Item* Content
Corrected item-
to-domain/scale
correlation†
Cronbach’s
α
Corrected item-
to-domain/scale
correlation†
Cronbach’s
α
Corrected item-
to-domain/scale
correlation†
Cronbach’s
α
Memory
(seven
items)
CogM9 I have had trouble ﬁnding my way to a
familiar place.
0.405‡ 0.828 0.430‡ 0.835 0.372‡ 0.817
CogM10 I have had trouble remembering where I
put things, like my keys or wallet.
0.590 0.587 0.595
CogM12 I have had trouble remembering new
information, like phone
numbers or simple instructions.
0.497‡ 0.514 0.469‡
CogC33c I have had to use written lists more
often than usual so I would not forget
things.
0.575 0.608 0.533
CogPM1 I have been able to remember things,
like where I left my keys or wallet.
0.645 0.655 0.631
CogPM2 I have been able to remember to do
things, like take medicine or buy
something I need.
0.607 0.584 0.643
CogPCH2 My memory is as good as it has always
been.
0.662 0.652 0.676
Verbal ability
(six items)
CogV13 I have had trouble recalling the name of
an object while talking to someone.
0.621 0.857 0.613 0.864 0.639 0.854
CogV15 I have had trouble ﬁnding the right
word(s) to express myself.
0.702 0.746 0.674
CogV16 I have used the wrong word when I
referred to an object.
0.640 0.677 0.584
CogV17b I have had trouble saying what I mean
in conversations with others.
0.737 0.729 0.752
CogC33a I have had to work harder than usual to
express myself clearly.
0.705 0.707 0.702
CogPV1 I have been able to bring to mind words
that I wanted to use while talking to
someone.
0.545 0.532 0.556
Concentration
(four items)
CogC7 I have had trouble concentrating. 0.608 0.813 0.670 0.831 0.553 0.789
CogC31 I have had to work harder than usual to
keep track of what I was doing.
0.648 0.660 0.632
CogPC1 I have been able to concentrate. 0.644 0.692 0.582
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Table 1 – continued
Combined FACT-Cog English
and Chinese versions
(N ¼ 328)
FACT-Cog English version
(n ¼ 185)
FACT-Cog Chinese version
(n ¼ 143)*
Domain/
Scale Item* Content
Corrected item-
to-domain/scale
correlation†
Cronbach’s
α
Corrected item-
to-domain/scale
correlation†
Cronbach’s
α
Corrected item-
to-domain/scale
correlation†
Cronbach’s
α
CogPF1 I am able to pay attention and keep
track of what I am doing without
extra effort.
0.630 0.622 0.638
Mental acuity
(four items)
CogA1 I have had trouble forming thoughts. 0.458‡ 0.803 0.514 0.829 0.418‡ 0.761
CogA3 My thinking has been slow. 0.717 0.736 0.689
CogC32 My thinking has been slower than
usual.
0.704 0.739 0.644
CogPCH1 My mind is as sharp as it has always
been.
0.549 0.577 0.516
Functional
interference
(four items)
CogF19 I have walked into a room and forgotten
what I meant to get or do there.
0.586 0.764 0.599 0.784 0.576 0.732
CogF23 I have had to work really hard to pay
attention or I would make a mistake.
0.607 0.610 0.591
CogF24 I have forgotten names of people soon
after being introduced.
0.587 0.589 0.582
CogF25 My reactions in everyday situations
have been slow.
0.586 0.573 0.593
Multitasking§
(four items)
CogMT1 I have trouble keeping track of what I
am doing if I am interrupted.
0.593 0.836 0.589 0.852 0.598 0.812
CogMT2 I have trouble shifting back and forth
between different activities that
require thinking.
0.589 0.550 0.611
CogPMT1 I am able to shift back and forth
between two activities that require
thinking.
0.628 0.547 0.722
CogPMT2 I am able to keep track of what I am
doing, even if I am interrupted.
0.582 0.550 0.599
Noticeability
(four items)
CogO1 Other people have told me I seemed to
have trouble remembering
information.
0.473‡ 0.743 0.490‡ 0.767 0.457‡ 0.707
CogO2 Other people have told me I seemed to
have trouble speaking clearly.
0.584 0.592 0.578
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which contains two items that investigate memory (“Have you
had difﬁculty remembering things?”) and attention deﬁcits
(“Have you had difﬁculty in concentrating on things, like reading
a newspaper or watching television?”) in the past week. This
QLQ-C30 cognitive functioning scale is used as an anchor for the
evaluation of test-retest reliability of the FACT-Cog.
BAI
The BAI is a validated questionnaire comprising 21 self-reported
anxiety-associated symptoms, the severity level of which
patients rate on a four-point Likert scale, ranging from 0 (“Not
at all”) to 3 (“Severe”) [23]. The score for the BAI ranges from 0 to
63 points. A higher BAI score is indicative of a higher level of
anxiety symptoms. Both the English and Chinese versions of the
BAI have been used to evaluate the presentation of anxiety-
related symptoms in patients with breast cancer in Singapore
[24].
Data Analysis
All statistical analyses were conducted with SPSS Statistics
Version 20. Missing values in the FACT-Cog, the QLQ-C30, and
the BAI were managed as stipulated by the respective question-
naire manuals. Descriptive statistics were used to describe the
demographic and clinical characteristics of the sample. A com-
parison was conducted regarding the baseline characteristics of
the English- and Chinese-speaking groups by using independent t
tests or Mann-Whitney U tests for continuous measures and chi-
square or Fisher exact tests for differences in categorical meas-
ures. All the two-tailed signiﬁcance tests were conducted by
using a P value signiﬁcance level of less than .05.
Validity
Assessing the validity of the FACT-Cog entailed that it measures
a patient’s self-reported cognitive complaints or perceived cog-
nitive functioning. A correlation analysis was performed between
the QLQ-C30 cognitive functioning scale and the total FACT-Cog
scores. The QLQ-C30 cognitive functioning scale was used
because it has been previously validated in multiple international
studies and in Singapore [21,22,25,26]. We hypothesized that the
FACT-Cog scores would correlate positively with the QLQ-C30
cognitive functioning scale.
A convergent validity analysis was performed to determine
whether the FACT-Cog total score correlated with its known
related constructs. Studies have shown that fatigue, anxiety,
and a poorer global health status have a negative effect on cancer
patients’ cognitive abilities [1–6]. By using the QLQ-C30 fatigue
scale and global health status rating, we hypothesized that a
lower FACT-Cog score would correlate with patients exhibiting a
higher level of fatigue and a decreased global health status rating.
By using the total score from the BAI, we hypothesized that a
lower FACT-Cog score would correlate with patients exhibiting
higher BAI scores or more severe anxiety.
In all the above correlation tests for concurrent and conver-
gent validities, an absolute correlation coefﬁcient value of 0.7 and
above was indicative of a strong correlation, an absolute corre-
lation coefﬁcient value of 0.4 to 0.7 indicated a moderate corre-
lation, and an absolute correlation coefﬁcient value between 0
and 0.4 indicated a weak correlation [27].
Known-group validity was performed to determine the sig-
niﬁcance of the differences between the FACT-Cog scores of the
groups known to have varying degrees of perceived cognitive
impairment. Because FACT-Cog items were ﬁrst developed by
soliciting patient descriptions of cognitive problems postchemo-
therapy [1–9], we hypothesized that patients who had completed
V A L U E I N H E A L T H 1 6 ( 2 0 1 3 ) 1 0 0 1 – 1 0 1 31006chemotherapy at the point of survey administration would report
poorer cognitive functioning, reﬂected by lower FACT-Cog scores,
than would those who were not exposed to chemotherapy (also
termed as “chemotherapy-naive” patients).
A principal-component factor analysis was conducted to
ascertain the one-factor structure of each cognitive domain.
Unidimensionality would be conﬁrmed if only one component
of each cognitive domain had an eigenvalue of more than 1.0
(Kaiser-Guttman criterion) [28–31].
Reliability
The internal consistency reliability between the individual items
of the same cognitive domain was evaluated by using Cronbach’s
alpha [32]. A Cronbach’s alpha of 0.7 and above represented
satisfactory consistency. To identify problematic or irrelevant
items that were not consistent with the other items in the
domain, an item-to-domain correlation analysis was also per-
formed. The corrected item-to-scale correlation was calculated
for each item by removing the contribution of the item to the
domain score. Any items with a correlated item-to-scale correla-
tion of less than 0.5 were identiﬁed.
Approximately 4 to 6 weeks after baseline assessment, a random
sample of patients recruited between May and October 2012 was
invited to complete the FACT-Cog and respond to two anchor
questions that were obtained from the QLQ-C30 cognitive function-
ing domain in the same language again through interview during
their scheduled follow-up consultation at the clinic. The test-retest
reliability was investigated by determining the intraclass correlation
coefﬁcient (ICC) of the scores for the patients who completed the
follow-up assessment within 45 days and stated “no change” to the
two anchor questions [33,34]. This time frame was chosen because
oncology practitioners in our cancer institution typically arrange for
follow-up consultations with patients at least once every 45 days,
and on the basis of clinical observation that ambulatory patients
with breast cancer commonly do not experience signiﬁcant changes
in their HRQOL and cognitive functioning within a span of 45 days.
For individual patient assessment, an ICC of 0.7 or higher is
considered as “satisfactory.” The mean difference between the
baseline and follow-up total FACT-Cog scores and cognitive domain
scores were evaluated. Currently, minimal clinically important
difference (MCID) is not determined for the FACT-Cog; hence, we
deﬁned the MCID as 4% to 6% of the total score on the basis of
established guidelines [35,36]. Because the literature has shown that
cognitive changes experienced by patients with cancer are subtle in
nature [2,5], we selected the stricter and more conservative lower
limit of 4% as the MCID. Therefore, if the mean differences of the
baseline and follow-up scores were within 4% of the total FACT-Cog
or cognitive domain score, test-retest reliability would be considered
as “satisfactory.”
Measurement equivalence
The equivalence of English and Chinese FACT-Cog was eval-
uated by examining whether score differences between these
versions were clinically important. By using the methodology
for assessing therapeutic equivalence in clinical trials, the 95%
CIs of FACT-Cog total and cognitive domain score differences
were compared with predeﬁned equivalence margins to deter-
mine whether differences in scores were clinically important
or unimportant [37,38]. A multiple regression analysis was
performed to estimate the comparability of the mean scores
obtained from both versions after adjusting for demographic
and health differences and known related constructs that
might prompt a change in patients’ cognitive functioning. It
was important to adjust for the inﬂuence of these variables
when assessing the inﬂuence of language because observed
differences in FACT-Cog scores might be caused by thesedeterminants rather than by questionnaire language. Clini-
cally relevant factors that were decided a priori for adjustment
included age [39], years of education [40], receipt of comple-
mentary alternative medicine (gingko [41], traditional Chinese
medicines, vitamins and nutritional products [42–46]), meno-
pausal status [47,48], hemoglobin levels [49], receipt of chemo-
therapy, anxiety (depicted by BAI scores) [6], fatigue (depicted
by QLQ-C30 fatigue scale scores) [50–52], HRQOL (depicted by
QLQ-C30 global health status scale) [53], cancer stage [54], and
receipt of endocrine therapy [40,55–57]. To adjust for the other
exploratory variables in the model, these variables must be
statistically signiﬁcant at a cutoff P value of .05 in the
univariate analysis, considered clinically relevant and postu-
lated to contribute to the clinical presentation of cognitive
impairment in patients with breast cancer, based on the
consensus among the clinicians in the research team. This
approach was adopted to prevent detraction from the statis-
tical power by including clinically irrelevant variables in the
model. Equivalence was established if the 95% CI of the
adjusted mean difference fell within the equivalence margin
of 0.25 SD. Should the 95% CI fall out of 0.25 SD, the
equivalence is still acceptable if it does not exceed 0.5 SD,
which is the threshold or upper limit for a small detectable
change [37].Results
Patient Characteristics
A total of 328 patients participated in the study, of which 185
(56.4%) were English-speaking and 143 (43.6%) were Chinese-
speaking (Table 2). The mean age of all the patients was 51.8 
9.7 years. The majority of the patients were Chinese (86.2%) with
early-stage breast cancer. Statistically signiﬁcant differences
were not observed among the demographic and clinical charac-
teristics such as marital status, hemoglobin level, presence of
comorbidities, cancer staging, Eastern Cooperative Oncology
Group, receipt of endocrine therapy, chemotherapy, and comple-
mentary alternative medicine. The Chinese-speaking patients,
however, were older than their English-speaking counterparts
(55.1  8.3 years vs. 49.3  10.0 years, P o .001). Compared with
the English-speaking patients, the Chinese-speaking patients
generally had fewer years of education (11.8  1.0 vs. 7.4  2.5,
Po .001), were unemployed (44.9% vs. 60.8%, P ¼ 0.005), and were
largely postmenopausal (51.9% vs. 63.6%, P ¼ .034). These dem-
ographic and health differences could be attributed to the
disparity in ages between the English- and Chinese-speaking
patients.
Questionnaire Scoring
FACT-Cog
The mean scores for FACT-Cog total and domains scores are
summarized in Table 3. The mean FACT-Cog total score for all
patients was 127.0  19.6. The English-speaking patients reported
a mean cognitive functioning score of 127.3  20.7, while the
Chinese-speaking patients reported a mean cognitive functioning
score of 126.6  18.0. Total FACT-Cog scores and cognitive
domain scores for English and Chinese versions did not differ
statistically, with the exception of the multitasking domain. (This
will be discussed further under the Measurement Equivalence of
the English and Chinese Versions section.)
QLQ-C30
The mean cognitive functioning scores from the QLQ-C30 showed no
statistical differences between the English- and Chinese-speaking
Table 2 – Baseline demographic, clinical, and medication information of patients (by total and language
versions).
Total (N ¼ 328) English-speaking
patients (n ¼ 185)
Chinese-
speaking patients
(n ¼ 143)
P
Frequency % Frequency % Frequency %
Demographic information
Age (y), mean  SD 51.82  9.7 – 49.31  10.0 – 55.05  8.3 – o.001
Age range (y)
21–30 8 2.5 8 4.3 0 0.0 o.001
31–40 39 11.9 32 17.3 7 5.0
41–50 90 27.4 60 32.4 29 20.2
51–60 131 39.9 60 32.4 71 49.7
460 60 18.3 25 13.6 36 25.1
Education (y), mean  SD 9.92  3.9 – 11.82  1.0 – 7.44  2.5 – o.001
Education (levels) o.001
Low education 85 25.9 12 6.5 73 51.1
None 10 3.0 0 0.0 10 7.0
Elementary/middle 75 22.9 12 6.5 63 44.1
High education 243 74.1 173 93.5 70 48.9
Junior high 151 46.0 91 49.2 60 42.0
Senior high 38 11.6 32 17.3 6 4.2
Graduate/postgraduate 54 16.5 50 27.0 4 2.7
Race o.001
Chinese 257 86.2 114 61.6 143 100
Non-Chinese 71 13.8 71 38.4
Malay 46 15.4 46 24.9 0 0.0
Indian 14 4.7 14 7.6 0 0.0
Others 11 3.7 11 5.9 0 0.0
Marital status .673
Single 61 18.6 35 18.9 26 18.2
Married 242 73.8 135 73.0 107 74.8
Divorced 16 4.9 11 5.9 5 3.5
Widowed 9 2.7 4 2.2 5 3.5
Employment status .005
Employed 158 48.2 102 55.1 56 39.2
Unemployed 170 51.8 83 44.9 87 60.8
Clinical information
Hemoglobin level (g/dL), mean  SD 11.76  2.2 – 11.55  2.4 – 12.03  1.8 – .057
Menopausal status .034
Premenopausal 187 57.0 89 48.1 52 36.4
Postmenopausal 141 43.0 96 51.9 91 63.6
Presence of comorbidities .070
Yes 96 29.3 46 24.9 50 35.0
No 232 70.7 139 75.1 93 65.0
Cancer staging .658
1 74 22.6 44 23.8 30 21.0
2 147 44.8 78 42.2 69 48.3
3 84 25.6 48 25.9 36 25.2
4 23 7.0 15 8.1 8 5.6
Time since diagnosis (mo), median (IQR) 20.2 (12.7–34.4) 19.2 (12.4–34.2) .375
ECOG .662
0 270 82.3 156 83.4 116 81.1
1 58 17.6 31 16.6 27 18.9
Medication information
Receipt of endocrine treatment .499
No 259 79.0 149 80.5 106 74.1
Yes 69 21.0 36 19.5 37 25.9
Tamoxifen 46 24 23
Aromatase inhibitors 23 12 10
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Table 2 – continued
Total (N ¼ 328) English-speaking
patients (n ¼ 185)
Chinese-
speaking patients
(n ¼ 143)
P
Frequency % Frequency % Frequency %
Time since endocrine treatment (mo), median
(IQR)
7.0 (3.0–13.0) 6.0 (3.0–11.0) 7.0 (2.5–14.0) .439
Completed chemotherapy .739
No 173 52.7 100 54.1 73 51.0
Yes 155 47.3 85 45.9 70 49.0
AC-based† 98 48 50
FEC-based‡ 32 17 15
Others 25 20 5
Receipt of complementary alternative medicine .184
No 155 47.3 93 50.3 62 43.4
Yes 173 52.7 92 49.7 81 56.6
Ginkgo extracts§ 12 6 6
Vitamin supplementsJ 122 74 48
TCM¶ 92 37 55
ECOG, Eastern Cooperative Oncology Group.
 Denotes statistically signiﬁcant (P o .05).
† AC-based: doxorubicin and cyclophosphamide-based.
‡ FEC-based: 5-ﬂurouracil, epirubicin, and cyclophosphamide-based.
§ Ginkgo extracts: Concentrated extracts or supplements that contain ginkgo, or derivatives of ginkgo.
J Vitamin supplements: Multivitamin supplements or health products.
¶ TCM, traditional Chinese medicine, refers to herbal supplements, concentrated extracts, or herbal concoction prescribed by a Chinese
physician or bought from a TCM pharmacy.
V A L U E I N H E A L T H 1 6 ( 2 0 1 3 ) 1 0 0 1 – 1 0 1 31008groups (88.1 17.9 and 89.6 14.2, respectively) (Table 4). Statistically
different scores, however, were observed between the English- and
Chinese-speaking patients in the following HRQOL domains of the
QLQ-C30: physical functioning (P ¼ .003), role functioning (P ¼ .0001),
emotional functioning (P ¼ .002), social functioning (P ¼ .004), fatigue
(P o .0001), and pain (P ¼ .036).
BAI
The BAI detected more anxiety symptoms among English-
speaking patients than among their Chinese-speaking counter-
parts (9.1  9.1 vs. 7.3  5.9, P ¼ .038) (Table 4).
Validity Assessment
Concurrent validity
A moderate-to-strong correlation between the FACT-Cog total
score and the QLQ-C30 cognitive functioning scale score was
observed for both the English and Chinese versions (r ¼ 0.725 and
0.646, respectively).
Convergent validity
The QLQ-C30 fatigue scale and the FACT-Cog total scores were
moderately-to-poorly correlated for the English and Chinese
versions (r ¼ 0.376 and 0.448, respectively). The correlations
between anxiety scores (the BAI total score) and the FACT-Cog
total scores for the English and Chinese versions were moderate
(r ¼ 0.589 and 0.567, respectively). The correlations between
the QLQ-C30 global health status score and the FACT-Cog total
score were moderate among the English-speaking patients (r ¼
0.580) and Chinese-speaking patients (r ¼ 0.511).
For both language versions, the correlations between individ-
ual cognitive domains and the known-related constructs of
fatigue, global health status, and anxiety were weak to moderate
(|r| ¼ 0.345–0.577, all P o .05).Known-group validity
Both versions of the FACT-Cog were able to discriminate between
patients who had completed chemotherapy and those who were
not exposed to chemotherapy. Both English-speaking and
Chinese-speaking patients who received chemotherapy reported
more cognitive disturbances than did patients who had no prior
exposure to chemotherapy (English-speaking: 123.1  23.8 vs.
130.9  17.0, P ¼ .010; Chinese-speaking: 122.0  17.9 vs. 131.0 
17.0, P ¼ .008).
With regard to the individual cognitive domains, patients
receiving chemotherapy reported consistently lower scores than
did those who were not exposed to chemotherapy (all P o .01).
Known-group validity between chemotherapy-receiving and
non–chemotherapy-receiving patients, however, was not
achieved for the subdomain of “noticeability” for both English-
and Chinese speaking patients (English-speaking: 14.9  2.2 vs.
14.4  1.3, P ¼ .064; Chinese-speaking: 15.1  1.4 vs. 15.3  1.6,
P ¼ .082).Factor analysis
For both language versions, unidimensionality was derived from
factor analysis for the domains of “concentration,” “verbal abil-
ity,” “functional interference,” “multitasking,” “noticeability,” and
“impact on quality of life,” suggesting that the individual items
within these domains could be summed to generate a single
domain score. The cumulative single items for the above
domains accounted for 67.3% to 74.2% of the total variance for
both languages, and the loadings of the items on each single
domain were similar and high.
Unidimensionality, however, was not conﬁrmed for the mem-
ory and mental acuity domains. It was noted that two items
(CogM9 and CogA1) were poorly loaded to their respective
domains of memory and mental acuity.
Table 3 – Results and measurement equivalence between English and Chinese versions of the FACT-Cog.
(Theoretical
score range)
Mean  SD Mean SD
Total
(N ¼ 328)
English-
speaking
(n ¼ 185)
Chinese-
speaking
(n ¼ 143)
English vs. Chinese
Equivalence
margin
(0.25 SD)
Equivalence
margin
(0.5 SD)
Adjusted
difference*
95% CI of
adjusted
difference
FACT-Cog total
score (0–148)
127.00  19.6 127.33  20.7 126.57  17.9 4.889 9.778 3.063 1.121 to 7.247
Domains
Memory (0–28) 23.50  4.1 23.68  4.3 23.25  3.9 1.029 2.059 0.660 0.311 to 1.631
Verbal ability
(0–24)
21.15  3.5 21.15  3.6 21.14  3.3 0.862 1.723 0.346 0.495 to 1.186
Concentration
(0–24)
13.50  2.7 13.72  2.8 13.22  2.5 0.669 1.338 0.606 0.7445 to 1.212
Mental acuity
(0–16)
13.50  2.8 13.53  3.0 13.46  2.5 0.692 1.383 0.329 0.297 to 0.954
Functional
interference
(0–16)
13.68  2.5 13.73  2.8 13.61  2.4 0.622 1.244 0.197 0.407 to 0.800
Multitasking†
(0–16)
13.08  2.8 13.43  2.8 12.64  2.7 0.704 1.408 0.846 0.185 to 1.506†
Noticeability
(0–16)
15.22  1.7 15.23  1.6 15.20  1.6 0.418 0.836 0.088 0.333 to 0.510
Impact on
quality of life
(0–16)
13.38  3.8 12.82  4.3 14.11  2.9 0.944 1.887 0.057 0.853 to 0.740
FACT-Cog, Functional Assessment of Cancer Therapy-Cognitive Function.
 Mean difference adjusted to clinically relevant variables that were decided a priori: age in years, education in years, receipt of
complementary alternative medicines, menopausal status, hemoglobin level, receipt of chemotherapy, anxiety, fatigue, global health
status, stage and receipt of endocrine therapy, and variables that showed statistical differences between the English- and Chinese-speaking
groups in Tables 2 and 4: race (Chinese vs. non-Chinese), work status (employed vs. unemployed), presence of comorbidities, physical
functioning, role functioning, emotional functioning, and social functioning.
† Denotes that the 95% CI exceeded both the 0.25 SD equivalence margin and the 0.5 SD equivalence margin threshold.
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Internal consistency and item-to-scale correlation
The Cronbach’s alpha for the English- and Chinese-speaking
patients’ FACT-Cog cognitive domain scores ranged from 0.707
to 0.929 (Table 1). The Cronbach’s alpha for the Chinese version
was generally observed to be lower than that for the English
version for all domains. There were, however, satisfactory inter-
nal consistencies within each of the domains for both languages.
The item-to-domain analyses identiﬁed four items that had
poor correlations (r o 0.500) with the other items in the same
domain: CogM9 and CogM12 from the memory domain, CogA1
from the mental acuity domain, and CogO1 from the noticeability
subscale.Test-retest reliability
A total of 152 patients were approached for the follow-up assess-
ment, of which 145 patients (95.4%) completed the FACT-Cog
questionnaire for the test-retest reliability analysis. Of these 145
patients, 70 (48.3%) patients indicated “no change” to the anchor
questions from the QLQ-C30 cognitive functioning scale and their
results were considered valid for analysis. Thirty-nine (55.7%)
were English-speaking patients, and 31 (44.3%) were Chinese-
speaking patients. The mean duration from baseline to follow-up
assessment was 40.9  21.2 days. The ICC values for the FACT-
Cog total score were satisfactory for both English and Chineseversions (ICC 0.762 and 0.697, respectively). The mean difference
between the baseline and follow-up total FACT-Cog scores was
1.01 points (95% CI 3.98 to 1.95), which was much lower than
the predeﬁned MCID of 5.9 points (4% of the total FACT-Cog
score).
The test-retest reliabilities for the individual cognitive
domains were fairly satisfactory, as indicated by ICC values
ranging from 0.673 to 0.793. All the ICC values for the individual
cognitive domains were above 0.7, with the exception of the
Chinese “mental acuity” domain (ICC 0.673). For all cognitive
domains, the mean differences between the baseline and follow-
up cognitive domain scores ranged from 1.2% to 3.8%, and all fell
within the predeﬁned minimal clinically important threshold of
4.0% of the total domain scores.
Measurement Equivalence of the English and Chinese
Versions
All clinically relevant variables that were decided a priori under
the methodological section and all statistically signiﬁcant varia-
bles in Tables 2 and 4 were adjusted in the regression model for
evaluating measurement equivalence between English and Chi-
nese versions (Table 3), with the exception of the variables
“nausea and vomiting” and “dyspnea” because it is irrelevant or
illogical to demonstrate that they contribute to the subtle cogni-
tive impairment in patients with cancer. The ﬁnal regression
model showed that signiﬁcant difference was not observed
Table 4 – Comparison of quality of life and anxiety between English- and Chinese-speaking patients.
Mean  SD
Total (N ¼ 328) English-speaking (n ¼ 185) Chinese-speaking (n ¼ 143) P*
EORTC-QLQ-C30
Global QOL†
Global health status 69.30  18.8 69.65  18.3 68.85  19.5 .668
Functional†
Physical 84.39  15.3 82.20  17.6 87.23  11.0 .003*
Role 85.36  18.7 80.90  20.9 91.14  13.4 .001*
Emotional 79.27  19.8 76.40  22.4 82.99  14.9 .002*
Cognitive 88.77  16.4 88.11  17.9 89.62  14.2 .364
Social 82.57  22.6 79.40  25.2 86.71  17.9 .004*
Symptom scales‡
Fatigue 28.00  21.2 32.31  23.1 22.45  17.1 .000*
Nausea and vomiting 3.43  9.8 5.13  12.0 1.28  5.3 .000*
Pain 17.07  20.8 19.19  23.4 14.33  16.5 .036*
Single items‡
Dyspnea 11.78  19.9 14.78  23.0 7.93  14.2 .002*
Insomnia 24.44  30.5 27.02  33.9 20.74  25.0 .054
Appetite 12.12  22.8 13.87  24.4 10.02  20.6 .145
Constipation 11.17  22.1 10.60  22.0 11.89  22.2 .627
Diarrhea 3.76  13.1 3.06  12.3 4.66  14.0 .263
Financial 32.12  34.2 32.26  34.9 31.93  33.3 .931
BAI
Total§ 8.30  8.0 9.07  9.1 7.29  5.9 .038*
BAI, Beck Anxiety Inventory; EORTC-QLQ-C30, European Organization for Research and Treatment of Cancer Quality of Life Core Questionnaire
30; QOL, quality of life.
 Denotes statistically signiﬁcant (Po .05). All variables that are statistically different between the two groups were adjusted in the regression
model for evaluating measurement equivalence between English and Chinese versions (Table 3), with the exception of the variables “nausea
and vomiting” and “dyspnea” because it is irrelevant or illogical to demonstrate that they contribute to the subtle cognitive impairment in
patients with cancer.
† A higher score is indicative of a better functioning/health status. The theoretical range for the global and functional scales is 0 to 100.
‡ A higher score is indicative of more symptoms/difﬁculties. The theoretical range for the symptom scales and single items is 0 to 100.
§ A higher score is indicative of more symptoms/difﬁculties. The theoretical range for the BAI is 0 to 63.
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cognitive domains of memory, verbal ability, concentration,
mental acuity, and functional interference or in the subscales
of noticeability and inﬂuence on quality of life. Ninety-ﬁve
percent of the CIs for the adjusted difference between the scores
of both languages fell within the 0.5 SD margin. The 95% CI of
the difference in scores between the English and Chinese ver-
sions in the multitasking domain, however, fell outside the 0.25
SD equivalence margin and exceeded the 0.5 SD threshold or
upper limit for a small detectable change. This suggests that the
equivalence between the English and Chinese versions was
questionable in the multitasking domain.Discussion
This is the ﬁrst study to evaluate the validity, reliability, and
equivalence of the English and Chinese versions of the FACT-Cog.
Our results reveal that both versions of the FACT-Cog are
equivalent, valid, and reliable to a great extent in assessing the
perceived cognitive functioning of Asian patients with breast
cancer. An adaptation of the FACT-Cog in the sociocultural
context of Asian population and the evaluation of its psycho-
metric properties is essential to the accurate interpretation of
results in clinical studies [5].
The results obtained from the concurrent validity analysis
demonstrated that the English and Chinese FACT-Cog total
scores had strong and moderate correlations, respectively, withthe validated QLQ-C30 cognitive functioning scale. The conver-
gent validity analysis revealed that the correlations between the
FACT-Cog total scores and patients’ anxiety, fatigue, and global
quality-of-life level were weak to moderate. Similar results were
observed in the validation of the English FACT-Cog (version 2) in
101 patients with cancer who underwent hematopoetic stem cell
transplantation; the correlation between FACT-Cog total scores
and the constructs of depression, anxiety, and fatigue were weak
to moderate (IrI ¼ 0.36–0.60) [13]. A strong correlation was not
obtained, likely because of the multifactorial nature of cognitive
impairment, which consists of various clinical, pharmacological,
and psychosocial confounders such as depression, receipt of
neurodegenerative drugs, distress, mood changes, and the
patients’ genetic predispositions [58–60]. Furthermore, it has been
proposed that interacting effects might exist among psycholog-
ical, psychosocial, and demographic factors in the “chemobrain”
phenomenon [1,61]. Therefore, no single attribute is sufﬁcient to
create a strong correlation with greater perceived cognitive
impairment. In the validation study, the choice of fatigue,
anxiety, and HRQOL as the constructs of interest was valid
because these variables have been substantially described in
the literature as associated with perceived cognitive functioning
[6,50–53].
Results from known-group validity analysis suggested that
both versions of the FACT-Cog were able to discriminate patients
on the basis of their chemotherapy treatment status. Choice of
known-groups in the assessment of perceived cognitive function-
ing poses a challenge for this validation study. Receipt of
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of other potential choices, such as presence of brain metastases
[62,63], receipt of brain radiation therapy [64], and other severe
neuropsychiatric disorders such as dementia or Alzheimer’s
disease [65,66]. These conditions can potentially lead to cognitive
decline in patients. Because this study aims to validate the
capability of the FACT-Cog to detect subtle cognitive changes in
patients with cancer, neuropsychological conditions that drasti-
cally affect brain functioning may generate extreme results and
are not suitable for this purpose. To complement our results, it is
recommended that future work should consider administering
the FACT-Cog to healthy individuals in order to get normative
values for the general population [14].
We also scrutinized the validity, reliability, and measurement
equivalence of a subjective neuropsychological assessment on
the basis of its cognitive domains, instead of its originally
proposed subscales or a global scale. It is noted that self-
reporting tools most commonly use a global or summary scale
rather than the speciﬁc domains of cognitive complaints.
Although earlier studies have shown that the results of objective
and subjective neuropsychological assessments do not correlate,
some research has suggested otherwise when results are com-
pared according to speciﬁc domains rather than overall scores
[18,19,67,68]. In future research, the criterion validity of the FACT-
Cog could be conducted by examining the relationship between
the speciﬁc domains of subjective cognitive complaints and
objective neuropsychological batteries.
Both versions of the FACT-Cog have demonstrated satisfac-
tory internal consistencies among the cognitive domains and
test-retest reliability. Factor analyses and item-to-domain corre-
lations have also revealed that the majority of the items in the
FACT-Cog relate well to the constructs of their respective cogni-
tive domains. CogM9 and CogM12, however, were highlighted as
problematic items within the memory domain. Because these
results were observed in both the English and Chinese versions,
the poor item-to-domain correlations could be due to problems
with the original item, rather than translation errors. For CogM12,
we postulate that using patients’ ability to remember “phone
numbers” and “simple instructions” to assess memory may not
be relevant in today’s context. Most patients need not remember
such information, given the prevalence of technologies (e.g.,
mobile phones) that provide easy information storage and recall.
We also observed that within the memory domain, CogM9 was
identiﬁed as a problematic item that deviated from its underlying
construct of memory. This could be due to the ambiguous nature
of the content outlined by the item. The patients’ inability to ﬁnd
their way to a “familiar place” might be indicative of a severe or
clinically signiﬁcant cognitive impairment, instead of the mild or
subtle cognitive changes often observed in patients with cancer.
Furthermore, many patients may have difﬁculty understanding
the term familiar place because it is poorly deﬁned and not tied to
concrete examples.
Poor item-to-domain correlations were also observed with
CogO1 and CogO4 for both language versions. A similar validation
study of the French version of the FACT-Cog also identiﬁed CogO1
as having a poor item-to-total correlation within the subscale of
“noticeability” (r ¼ 0.32) [14]. Moreover, the Chinese version of the
noticeability domain could not differentiate patients who had
completed chemotherapy from those who were not exposed to
chemotherapy. This could be due to the sensitive nature of these
items, which seek to obtain a third party’s opinion of the
patient’s cognitive ability. When applied in the context of an
Asian population that values communal living and kindred
spirits, these comments are expected to be poorly received. The
Asian patients with breast cancer who participated in one focus
group study expressed that their family members provided them
with good psychosocial support during their chemotherapytreatment, and were generally “forgiving and patient towards
them” when they displayed cognitive lapses [5]. Thus, the
responses to CogO1 and CogO4 may not be accurately reﬂected.
It was observed that the test-retest reliability is only fairly
satisfactory (ICC 0.673) for the mental acuity domain. CogA1 was
also identiﬁed by the factor analysis as relating poorly to the
constructs of the mental acuity cognitive domains, especially
within the Chinese version of the FACT-Cog. Poor item-to-
domain correlation observed with the Chinese FACT-Cog, which
was not observed with the English FACT-Cog, suggests that
cultural differences might have led to differential interpretations
of the same item [5]. Despite repeated attempts to rephrase and
reﬁne this item during the pretesting stage, the phrase “trouble
forming thoughts” is potentially open to misinterpretation and
difﬁcult to understand by patients. This was also observed with
the validation of the French FACT-Cog, which required modiﬁca-
tions to the translation of “forming thoughts” in the pretesting
phase [14]. To improve comprehensibility and to ensure equiv-
alence with the English source, we propose that retranslation and
validation of CogA1 is needed. Caution must be taken in the
interpretation of the mental acuity domain, particularly the
Chinese version.
We also evaluated the measurement equivalence between the
English and Chinese versions of the FACT-Cog. Although most
cross-cultural patient-reported outcome study groups had under-
gone a vigorous translation process to ensure the content and
semantic equivalence of the translated tool, it is imperative to
evaluate the comparability and equivalence between the English
and non-English versions of the FACT-Cog, because there is no
assurance that the translated tool is equivalent to the original
English version unless the comparability in the psychometric
properties of the two tools is performed [69]. Measurement
equivalence is necessary to facilitate the pooling of results from
multinational clinical trials and identify problematic items that
differ, in semantic structure, from the original language version
[70]. Our FACT-Cog scores were adjusted on the basis of both
clinically relevant and statistically signiﬁcant demographic and
health differences between both groups to evaluate the measure-
ment equivalence of both versions. With the understanding that
cognitive impairment in patients with breast cancer is a multi-
factorial phenomenon, we considered that adjusting for known
related constructs could enhance the accuracy of the equivalence
measure. Our analysis demonstrated that both versions are
equivalent for the total score and all the cognitive domains, with
the exception of the multitasking domain. Poor equivalence could
be due to translation errors or differences in the cultural under-
standing of the items. The items in the multitasking ability
domain involved asking patients about their ability to effectively
perform tasks that require simultaneous thought. Hence, the
difﬁculty and choice of tasks could be inﬂuenced by patients’
lifestyles and cultural preferences. Caution must be taken when
pooling the results of both language versions for this domain.
Retranslation and reﬁnement of the items are needed to improve
their equivalence with the English source.
This study has a few limitations. In the concurrent validity
analysis, the QLQ-C30 cognitive functioning scale consisted of
only two items to evaluate patients’ perceived concentration and
memory. This could be seen as a methodological limitation
because the QLQ-C30 is not the perfect standard for evaluating
the concurrent validity of the FACT-Cog. The FACT-Cog’s cogni-
tive domains and items include additional domains that are not
examined in the QLQ-C30. Our choice of the QLQ-C30 in this
validation exercise, however, is well justiﬁed because there are
no other validated questionnaires currently available that assess
all the domains of perceived cognitive impairment in local
patients with cancer. Finally, there was a lack of published
validation studies on the FACT-Cog for cross-referencing
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FACT-Cog on the basis of their corresponding domains and total
scores.
Future studies should evaluate the longitudinal validity and
responsiveness of the FACT-Cog to cognitive changes within
patients with breast cancer across separate time points. To
facilitate the interpretation of the clinical relevance of score
changes, identiﬁcation of MCID can guide the clinical interpreta-
tion of patient-reported cognitive changes by providing recogniz-
able end points. Finally, validation studies can be performed on
other cancer populations to support the use of the FACT-Cog in
oncology clinical and research settings.Conclusions
The FACT-Cog is a valid and reliable instrument for assessing
perceived cognitive functioning in Asian patients with breast
cancer. A few items within the “memory,” “mental acuity,” and
“noticeability” domains, however, feature content or examples
that are culturally irrelevant or inappropriate and one should be
cautious in interpreting results of these problematic items. The
English and Chinese versions of the FACT-Cog have also demon-
strated measurement equivalence. In addition, caution must be
taken when the results of both versions are pooled for items
within the multitasking domain. These items should undergo
cross-cultural adaptation and retranslation to improve compre-
hensibility across cultures and languages. Overall, the validity,
reliability, and measurement equivalence between the English
and Chinese versions complement and support the use of the
FACT-Cog as a tool for future clinical research.Acknowledgments
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